Purpose Oncological patients are at increasing risk of QT prolongation, a risk factor for ventricular arrhythmia. We assessed impact and risk factors for corrected QT (QTc) prolongation during multiple-cycle chemotherapy. Methods We enrolled 100 outpatients initiating chemotherapy in a university center specializing in female cancer. Clinical, drug, laboratory, and 12-lead ECG data collection at baseline and at each chemotherapy cycle was performed. Results Enrolled patients were followed for 992 chemotherapy cycles (median 7; interquartile range 6-13); 2438 ECGs were recorded (20; 18-31) 36.8 % pre-therapy, 36.8 % following chemotherapy, and 22.5 % 7-10 days after chemotherapy. Maximum QTc (Max-QTc) was recorded after 4 chemotherapy administrations in >50 % of the entire cohort and also within every subset of patients with prolonged QTc (57 % 471-480 ms; 54 % 481-500 ms; 66 % >500 ms). No cumulative effect on QTc was shown. QTc prolongation was comparable among the various protocols. Prophylactic/ supportive drugs were not associated with additional QTc prolongation. Variables independently associated with QTc prolongation >470 ms were age (OR 1.056 95 % CI 1.006-1.108, p=0.028) and the baseline-first chemotherapy averaged QTc (BC-QTc) (OR 1.092 95 % CI 1.051-1.136), a novel parameter devised for this study. Only BC-QTc maintained significance for QTc >480 ms. BC-QTc >435 ms identified 100 % of patients with Max-QTc >500 ms, 96 % with Max-QTc 481-500 ms, and 66 % with Max-QTc 471-480 ms. Only 29 % of patients with Max-QTc ≤470 ms presented a BC-QTc >435 ms. Conclusions Our results confirm the high prevalence of QTc prolongation after chemotherapy. Most of the patients reached Max-QTc after several cycles. BC-QTc may help in stratifying arrhythmic risk in real-world clinical practice.
Introduction
Sudden cardiac death (SCD) is a major clinical concern with an annual incidence of 50-100 per 100,000 people in industrialized countries [1] . The increasing number of reports on the arrhythmic risk of non-antiarrhythmic drugs has raised several concerns, especially for regulatory agencies [2, 3] . However, while most of the efforts have been oriented toward managing this risk in the process of new drug development, we still lack directives for common clinical practice. Oncology patients, Electronic supplementary material The online version of this article (doi:10.1007/s00228-015-1874-3) contains supplementary material, which is available to authorized users.
especially candidates for outpatient chemotherapy, represent a large subgroup of subjects at increased risk for drug-induced ventricular arrhythmias, for which we lack any guidance for risk stratification and follow-up strategies [4, 5] . QT interval is still the best, albeit imprecise, parameter to identify alterations of cardiac repolarization, and its prolongation is the most common reason for FDA restriction to approval of all noncardiovascular drugs [6] .
Available studies in oncology present several limitations in terms of population size, follow-up, and specificity of clinical settings [7] [8] [9] , which hamper the development of a definite strategy to stratify the arrhythmic risk and manage these patients in real-world clinical practice [10] . This prospective cohort study was conceived to provide reliable estimates on the incidence of QT prolongation during multiple cycles of different chemotherapy protocols including standard prophylactic/supportive therapy. We also explored possible predictors of corrected QT (QTc) prolongation to improve risk stratification.
Patients and methods

Patient populations
All consecutive candidates to initiate chemotherapy as outpatients between April 2010 and November 2012 at the Center for Female Solid Cancers were considered for this prospective cohort study. This cohort was chosen on the basis of the following three main considerations: (1) outpatients are at higher risk of adverse outcomes in case of arrhythmic complications, (2) restriction to female cancer overcomes the confounding effect of gender, while addressing a population at increased risk of drug-induced arrhythmias [11] , and (3) possibility to test various types of chemotherapy protocols within a quite homogeneous population. None of these patients underwent chemotherapy in the 12 months before the study entry. Relevant cardiac dysfunction was excluded before starting the treatment by anamnestic, clinical, and echocardiographic evaluations.
The following exclusion criteria were applied: 
Data collection and follow-up
The baseline evaluation for all patients consisted of detailed health interview and clinical examination, 12-lead ECG, and blood analysis (hemochrome, coagulation, serum electrolytes, thyroid, renal, and hepatic function). Subsequent checks were scheduled according to the specific chemotherapy protocol. They consisted of a brief interview, clinical evaluation, and a 12-lead ECG, while laboratory was repeated before each cycle. These checks were grouped into: (a) Pre-therapy ECG, the day before chemotherapy; (b) Chemotherapy ECG, the day of chemotherapy (between 1 to 3 h after the i.v. infusion); and (c) Control ECG, 7-10 days after chemotherapy (variable according to each scheme). The ECGs were digitally recorded with a MAC 1600 (GE Healthcare, Little Chalfont, UK) with built-in software for QT interval measurement/correction. Each ECG was sampled twice by a trained operator within a few minutes, to avoid loss of data. They were subsequently reviewed by two cardiologists.
To provide a real-world approach, only the first ECG was considered for measurement of the parameters (PR duration, QRS duration, RR cycle length, heart rate, QT and QTc interval duration) unless the quality of the first ECG was inadequate or the second ECG provided a variation of QTc value >10 ms [12] . In the latter case, the mean of the two QTc values was used in spite of the first measurement. QT intervals were corrected according to Bazett's formula (QTc=QT/√RR, RR interval expressed in seconds) since this equation, albeit less precise at very low/high heart rates, is the one most frequently adopted in clinical practice and QTc studies.
Several cutoff values have been proposed for QTc, since a definite safety-threshold has never been identified. We decided to consider the cutoffs most widely adopted in both clinical/ experimental cardiological settings (i.e., 450, 470, and 500 ms; for adult females) [13, 14] together with the value of 480 ms, identified by the most recent guidelines for reporting chemotherapy-associated adverse events [10] . This lead to a four QTc interval scale: normal <450 ms, borderline 450-470 ms, slightly increased 471-480 ms, moderately increased 481-500 ms, and severely increased >500 ms. We also evaluated the difference of QTc values between two consecutive ECGs, named delta QTc. According to previous literature, the cutoff values considered in our study (to balance sensitivity and specificity) were normal <30 ms (within normal day-to-day variability), borderline 30-60 ms, and increased >60 ms [10, 15, 16] .
Statistical analysis
Normal distribution of the variables was assessed with Shapiro-Wilk test: parametric/non-parametric statistic was adopted in accordance. Continuous variables with/ without normal distribution are expressed as mean±SD or [median; interquartile range] in accordance. Categorical variables are expressed in terms of fraction and percentages. Comparisons between baseline and after the first chemotherapy cycle were performed using the paired Student's t test or Wilcoxon test (when appropriate) and Fisher's exact test. The same tests were used to compare QTc recorded on the chemotherapy ECG with the value at pretherapy and control ECGs within the same chemotherapy cycle. The Kruskal-Wallis test was used to assess differences in QTc values among the four types of ECG (i.e., baseline, pre-therapy, chemotherapy, control). We assessed any variation of QTc values among the same types of ECG (i.e., pre-therapy, chemotherapy, control) during subsequent cycles with the Friedman test to explore a possible additive effect on myocardial repolarization after multiple cycles. The Bonferroni correction was applied for multiple comparisons. To identify possible predictors of recording any QTc >470 and >480 ms over the entire period of follow-up, we performed a multivariate logistic regression analysis inserting variables that reached p<0.05 at univariate logistic regression analysis. Receiver operating characteristic (ROC) curves were produced to identify cutoff values (with adequate sensitivity/ specificity values) for these predictors (when continuous), included in the final logistic regression analysis. Statistical analysis was done using SPSS version 17.0.3 (SPSS, Inc. Chicago, IL), p values < 0.05 were considered significant. Table 1 summarizes the baseline data of the 100 consecutive patients enrolled. Notably, nine patients presented a previous, unrelated, cancer. According to the enrollment criteria, no relevant cardiovascular disease was present in any of the patients.
Results
Study population
All the baseline laboratory values were within the normal range, with the exception of TSH values in three cases: one suppressant therapy for prevention of relapses of a thyroid cancer and two patients with under-titration of L-tiroxin supplementation (promptly corrected at the following clinical checks). Tables 1 and 2 show ECG-related parameters recorded at baseline and after the first chemotherapy cycle. According to the baseline 12-lead ECG, all the enrolled patients were in sinus rhythm in the absence of significant conduction disturbances (according to enrollment criteria). QTc values at baseline were above 450 ms in 18 patients, while two patients presented a QTc above 470 ms (475 and 479 ms, respectively).
Chemotherapy protocols
The enrolled patients underwent multiple chemotherapy protocols according to the type of underlying cancer, the staging level, and the overall clinical status. Each protocol ACE-I angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers, BB beta-blockers, BDZ benzodiazepine, CCB calcium channel blocker, HR heart rate, PPI proton pump inhibitors, SSRI serotonin reuptake inhibitor a Drug with potential effect on QTc encompassed several cycles of the same combination of drugs and supportive therapy (see below). We followed all the subjects during all the available cycles in a study period of 3 years (April 2010 to April 2013). The enrolled patients were followed for 992 chemotherapy cycles overall with a median of 7 [6] [7] [8] [9] [10] [11] [12] [13] per patient. Table 3 depicts the chemotherapy regimens used in the enrolled population. The same table shows the supportive therapy included as a standard in the chemotherapy protocols that was in addition to the treatment already received by the patient at baseline (for associated comorbidities) or required for occurrence of particular side effects/diseases (e.g., nausea/vomiting or infections). (Fig. 1) , chemotherapy ECG scored a higher average QTc value with respect to the other three groups (p<0.001 for all the comparison at the Bonferroni corrected test). The comparison between the three remaining groups showed only a higher mean value of the control ECG with respect to baseline (p=0.03). Notably, the 6 ECGs (among 3 patients) with a QTc >500 ms were recorded the day of chemotherapy.
12-lead ECG follow-up and QTc modifications
Analysis of QTc from baseline to the sixth cycle (18 ECGs on average) was performed to unmask a possible cumulative effect ( figure S1 ). While the average QTc recorded on the chemotherapy ECG was greater than the respective pretherapy and control ECGs at all six cycles (p<0.001), no cumulative effect was evident with the exception of a significant increase in average QTc on the control ECG after the third with respect to the first cycle (p<0.03 at Friedman test). This result was confirmed in the subset of patients maintaining the same chemotherapy protocol for all 6 cycles (n=10). Figure 2a shows the maximum QTc (Max-QTc) recorded for all the 100 patients, considering the progressive number and timing of the ECGs: 82 % chemotherapy ECG, 9 % pretherapy ECG (1/9 at baseline), and 9 % control ECG. Notably, the Max-QTc was recorded after 4 chemotherapy administrations in >50 % of the entire cohort and also within every subset of patients with prolonged QTc (57 % 471-480 ms; 54 % 481-500 ms; 66 % >500 ms), as can be clearly seen in figure S2 . The same occurred for delta QTc (Fig. 2b) , especially for all the 5 patients with delta QTc >60 ms. Notably, only 6.89 % (168/2438) of the ECGs presented a QTc >470 ms, while 0.24 % (6/2438) presented a QTc >500 ms.
Specific chemotherapy protocols and co-administration of QTc-prolonging drugs Tables 1 and 3 summarize data on preexistent therapy, chemotherapy protocols, and supportive therapy. Figure S3 shows the comparison of average QTc on the chemotherapy ECGs among the six different types of chemotherapy protocols: 
Values represent mean±standard deviation or number (percentage)
HR heart rate, n.a. not applicable Table 3 Chemotherapy protocols according to the chemotherapy drugs and the standard supportive drugs used in the analyzed cohort (Table S1 ), they were used in 98 % of the patients throughout the follow-up and in 31.8 % (776/ 2438) of ECG (80 % 623/776 in the chemotherapy ECG). Notably, only seven patients were taking QT-prolonging drugs chronically and all continued these drugs throughout the follow-up, while many of the other drugs were administrated for prevention/treatment of chemotherapy side effects (antibiotics 16/100, ondansetron 98/100). While the average QTc value was slightly higher in patients under non-chemotherapy QTcprolonging drugs in the ECG recorded between the cycles (442 ms iqr. 428-452 vs. 437 ms 422-449 ms; p=0.01), this was not evident in the chemotherapy ECG (447 ms iqr. 433-463 vs. 447 ms iqr. 430-460; p=0.206). Moreover, if we consider the ECG with a prolonged QTc (>470 ms) in nonchemotherapy ECGs (n=48 overall), only 2/153 (1.3 %) were recorded under QTc-prolonging drugs vs. 46/1291 (3.5 %; p= 0.217).
Predictors of QTc prolongation
We performed a regression analysis to identify possible predictors of a QTc prolongation throughout the follow-up using the two more widely adopted cutoff values, 470 and 480 ms (respectively 46/100 and 25/100 patients). We tested all the available baseline characteristics (clinical, ECG, and laboratory) together with the ECG data belonging to the first cycle and the data on type of chemotherapy and supportive treatment. In view of the known variability of QTc values, we tested a new parameter, the baseline-first chemotherapy averaged QTc (BC-QTc), conceived to hamper this phenomenon while highlighting a reduced repolarization reserve (in response to chemotherapy). The parameters reaching significance at the univariate analysis were age, baseline QTc, first therapy QTc, BC-QTc, weight (only >470 ms), and body mass index (only >470 ms). The multivariate analysis showed the following as independent predictors: age (only for QTc >470 ms: OR 1.056 95 % CI 1.006-1.108, p=0.028) and BC-QTc (>470 ms: OR 1.092 95 % CI 1.051-1.136; >480 ms: OR 1.119 95 % CI 1.067-1.174). To provide cutoff values for current clinical practice with adequate sensitivity/specificity, we created two ROC curves for BC-QTc considering both the >470 ms and the >480 ms cutoff values (Fig. 3) , which also confirmed the high predictive performance of this parameter. When dichotomizing BC-QTc for the cutoff identified through ROC curves analysis (i.e., >/≤ 435 ms) the new OR were 36.000 (95 % CI 4.620-280.493) for predicting a QTc >480 ms and 11.281 (95 % CI 4.318-29.476) for predicting a QTc >470 ms. Based on our results, we produced a possible scheme (Fig. 4) for ECG follow-up of patients undergoing chemotherapy that was potentially able to provide a high level of sensitivity to QTc prolongation while avoiding unnecessary repeated ECG in most of (the low risk) patients.
Discussion
According to our results, QTc prolongation is fairly common in patients undergoing chemotherapy with current schemes: about a half of these patients will develop a QTc >470 ms and 3 % >500 ms. Notably, Max-QTc is reached very late (after four cycles in >50 % patients) without a clear pattern of increase. This finding raises concerns on patient monitoring, since many chemotherapy protocols require several cycles. Kitagawa et al. [7] previously reported a progressive increase in QTc value in 37 patients undergoing chemotherapy with fluorouracil-epirubicin-cyclophosphamide (FEC) for early breast cancer. They found a significant increase both in pretreatment ECGs and chemotherapy ECGs. The same finding was not replicated in our cohort of patients, also considering the subgroup of subjects undergoing the FEC protocol (data not shown). A possible explanation, apart from play of chance, may derive from a larger size of our population (67 vs. 37 patients with ≥3 FEC administrations), different study design (Kitagawa et al. [7] excluded patients taking other drugs with QTc-prolonging effect and they averaged QTc of 26-28 patients per cycle while in our study no chemotherapy ECG was lost until the end of follow-up), and the number of FEC administrations (i.e., the significance of QTc increase was found after the fourth FEC cycle which was performed in a restricted subgroup of our cohort). Despite these diversities, we found a significant increase of QTc value after all the chemotherapy cycles with respect to pre-treatment and control ECGs at least up to the sixth cycle. This on-off phenomenon seems to be reassuring, since we still lack definite data confirming that an acute post-treatment ECG without pathological QTc prolongation can provide adequate proof of freedom from late QTc prolongation (in view of possible concurrent factors affecting ventricular repolarization in the intercycle period). Moreover, while the Max-QTc was reached on the chemotherapy ECG by 81 % of the patients, this Fig. 3 Receiver operator curve analysis of baseline-first chemotherapy averaged QTc (BC-QTc) to predict development of QTc prolongation >470 ms (broken line) and >480 ms (continuous line). The included table reports sensitivity and specificity values for the three most suitable cutoff values occurred in 22/25 (88 %) of the subjects reaching a QTc >480 ms and in all three patients with a QTc >500 ms. Taken together, these findings support the practice of performing an (adequately timed) ECG the day of chemotherapy to guide QTc monitoring in these subjects.
Despite this positive finding, the absence of a plateau phenomenon for QTc increase coupled with the requirement of multiple chemotherapy protocols to prevent/treat malignancy recurrence (in our cohort only 6/100 patients underwent the same chemotherapy protocol), having different effects on myocardial ion currents [17, 18] , seem to hamper the development of a practical approach to identify patients at higher risk of ventricular arrhythmia. Moreover, none of the chemotherapy protocols evaluated in this study seemed to be associated with a higher QTc prolongation, a finding reinforced both by the direct comparison of average QTc recorded on chemotherapy ECGs among the 6 subgroups of protocols and by the absence of an association between each protocol (or compound) and a QTc prolongation >470/480 ms. These findings confirm previous reports showing a significant QTc prolongation by most of the chemotherapy agents used in current clinical practice [19, 20] , highlighting the need for a shift of our perspective from struggling to develop compounds free of arrhythmic risk to the development of strategies for risk management. Considering that drug-induced ventricular arrhythmias are extremely rare in subjects with a normal QTc, any strategy aimed at identifying subjects at high risk of developing a prolonged QTc can potentially target our preventive efforts. We assessed the predictors of significant QTc prolongation during our extended follow-up, demonstrating that patient age and QTc value both at baseline and after the first cycle are independently associated with a QTc >470/480 ms. We chose to average the value of baseline QTc with the first post-treatment QTc as a strategy to minimize the effect of the known day-to-day variability of QTc while maximizing possible underlying lack of repolarization reserve [12] . To fill the gap between the need for a careful follow-up of these patients and the feasibility of periodical ECG checks, we devised a simple scheme based on two QTc measurements (at baseline and after the first chemotherapy cycle) which provided a very good performance in our patient population (Fig. 4) . Future confirmation studies are required to support and, if necessary, refine this strategy.
Strength and limitations
This study was a non randomized, uncontrolled, prospective study of consecutive patients requiring different chemotherapy protocols and supportive therapy (according to clinician discretion). The sample size of the population enrolled was limited for feasibility considerations. Timing of the control ECG (not of pre-therapy or chemotherapy ECGs) was not strictly fixed for all the patients and was performed in about a half of the cycles. However, this is the largest unselected cohort of oncology patients with prolonged ECG monitoring including on and off treatment evaluation for consistency of Fig. 4 Scheme of ECG followup of candidates for outpatient chemotherapy according to the value of baseline-first chemotherapy averaged QTc (BC-QTc). The results of this scheme in the analyzed cohort are reported in bold italics effect, providing data on modification of ventricular repolarization in real-world clinical settings. Previous studies focused on highly selected populations usually undergoing a single drug/protocol [7] [8] [9] , involving a smaller number of patients. While providing interesting data on the effects of specific compounds, also giving insights on the interaction of the genetic substrate, they failed to provide the whole picture.
Conclusions
Our results confirm the high prevalence of QTc prolongation in oncology patients, reaching the Max-QTc after several chemotherapy cycles. Clinical, laboratory, and pharmacological data failed to predict the subsequent development of significant QTc prolongation (>470/480 ms). Possible explanations for this finding derive from the high number and heterogeneity of factors involved in repolarization reserve in each specific patient [3, 21] . However, we were able to develop a simple algorithm, based on QTc value recorded at baseline and after the first chemotherapy cycle, able to predict subsequent development of significant QTc prolongation with a very high sensitivity and a good specificity. While requiring future confirmation in larger subsets of patients, this is the first attempt to provide a practical albeit effective approach to stratify arrhythmic risk for chemotherapy candidates in the real-world clinical practice.
